Taken together, increased iron concentration in the tumor milieu caused by intravenous iron supplementation hampers activation, expansion, survival and functionality of the two key effectors of anti-tumor immunity, CD8+ cytotoxic T cells and CD4+ T helper cells (Figure 9). The gene discussed is CD8A; the disease is neoplasm.